Showing 8851-8860 of 20396 results for "".
- Neurocognitive Implications of Glycemic Extremes in Pediatric Type 1 Diabeteshttps://reachmd.com/news/neurocognitive-glycemic-extremes-pediatric-type-1-diabetes/2485101/A recent review links diabetic ketoacidosis, severe hypoglycemia, and chronic hyperglycemia to measurable neurocognitive and neuroimaging changes in children with type 1 diabetes. DKA at pres
- Risk for Developing Type 1 Diabetes Doubled with Paternal Linkhttps://reachmd.com/news/risk-for-developing-type-1-diabetes-doubled-with-paternal-link/2467871/by Lori Solomon Individuals are less likely to have type 1 diabetes if t
- Vitamin D₂ May Help Preserve Honeymoon Phase of Type I Diabeteshttps://reachmd.com/news/vitamin-d2-may-help-preserve-honeymoon-phase-of-type-i-diabetes/2462310/by Bob Yirka , Medical Xpress
- GLP-1 Receptor Agonist Therapy and Cardiorenal Outcomes in Type 1 Diabeteshttps://reachmd.com/news/glp-1-receptor-agonist-therapy-and-cardiorenal-outcomes-in-type-1-diabetes/2487734/Key Takeaways GLP-1-based therapy was associated with lower risks of all-cause mortality, heart failure, adapted MACE, and all-cause hospitalization in matched adults with type 1 diabetes. No significant differences were observed for myocardial infarction, i
- Harnessing Lifestyle and Innovation: Comprehensive Strategies for Type 2 Diabetes Managementhttps://reachmd.com/news/harnessing-lifestyle-and-innovation-comprehensive-strategies-for-type-2-diabetes-management/2483120/In the battle against Type 2 diabetes, healthcare is increasingly focusing on integrative approaches that combine lifestyle modifications with innovative pharmacological advancements, an approach aligned with ADA/EASD patient-centered guidance, presenting a promising horizon for man
- Delayed Puberty and Type 2 Diabetes: Investigating the Long-term Metabolic Impacthttps://reachmd.com/news/delayed-puberty-and-type-2-diabetes-investigating-the-long-term-metabolic-impact/2474595/Extensive research in Israel confirms that delayed puberty in boys is significantly linked to a heightened risk of developing type 2 diabetes in early adulthood—even when adjusting for factors like body weight and socio-economic status.
- Innovative Approaches to Safeguarding Beta Cells in Type 2 Diabeteshttps://reachmd.com/news/innovative-approaches-to-safeguarding-beta-cells-in-type-2-diabetes/2471823/Recent research from the Icahn School of Medicine at Mount Sinai identifies a novel approach to preserving beta cells, offering new hope in the management of type 2 diabetes by countering the detrimental effects of glucolipotoxicity. The breakth
- The Impact of Yo-Yo Dieting on Kidney Health in Type 1 Diabetes Patientshttps://reachmd.com/news/the-impact-of-yo-yo-dieting-on-kidney-health-in-type-1-diabetes-patients/2471159/What's New New evidence links yo-yo dieting to an increased risk of kidney disease in patients with Type 1 diabetes, highlighting the importance of weight stability. Significance The findings underscore the need for healthcare professionals to guide
- Enhancing Glycemic Control: Momordica charantia as an Adjunctive Therapy in Type 2 Diabeteshttps://reachmd.com/news/enhancing-glycemic-control-momordica-charantia-as-an-adjunctive-therapy-in-type-2-diabetes/2485369/In a real-world cohort of adults with type 2 diabetes inadequately controlled on metformin, adding a standardized Momordica charantia extract to metformi
- Navigating the Dual Burden of Type 2 Diabetes: Financial Strain and Digital Solutionshttps://reachmd.com/news/navigating-the-dual-burden-of-type-2-diabetes-financial-strain-and-digital-solutions/2475908/Patients with type 2 diabetes confront a dual burden: the direct health consequences of abnormal blood glucose levels, such as hyperglycemia or hypoglycemia, and the substantial financial strain imposed by high drug and treatment costs. The financial impact of type 2 diabetes is evid